Reposted by PaigeMatt Sikora @mjsikora.bsky.social · 03/03/2025Good news for #lobular: @theaacr.bsky.social #AACR25 now has an Advances session on ILC! AOS12 - New Findings in Invasive Lobular Breast Cancer: Histology Matters www.abstractsonline.com/pp8/#!/20273... Excited to be the intermission btw Steffi Oesterreich & Christina Curtis 😅. See you in Chicago!abstractsonline.comProgram Planner 062
Reposted by PaigeLaurence H. Tribe @tribelaw.bsky.social · 11/02/2025The ordinarily cautious and conservative ABA is blowing the whistle: The break-the-glass moment has arrived. www.americanbar.org/news/abanews... 13232521081
Reposted by PaigeShematologist, MD @shematologist.medsky.social · 08/02/2025When Elon was a kid, survival for ALL, the most common childhood cancer, was <10% Now it’s >90% due to funded collaboratives (high indirect costs) whose work ultimately SAVES THOUSANDS OF LIVES EVERY YEAR. For other cancers there’s still so much progress to be made. I think it’s worth it. 9747214
Reposted by PaigeWendy Woodward, MD, PhD @ibcradiation.bsky.social · 23/01/2025Contact your representatives- make sure they know what the impact of this is. #NIHsky #cansky #oncsky #IDsky 0107
Reposted by PaigeDana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · 15/01/2025Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer 🔓 pubmed.ncbi.nlm.nih.gov/39674130/ @antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social 0127
Reposted by PaigeStephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 22/12/2024Now online in JCO #postMonarch Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncskyascopubs.orgAbemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH TrialPURPOSECyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor re... 0205
Reposted by PaigeGeorge Sflomos @georgesflomos.bsky.social · 21/12/2024I'm excited to see ELBCC join the blue space! 🎉 Check out the terrific presentations from the #ILCSymposium 2024 in Leuven, which are all now available: youtube.com/@elbcc.europ..youtube.com 032
Reposted by Paige@doublewhammied @doublewhammied.bsky.social · 20/12/2024Did you miss #SABCS24 last week? No worries! Here's my @fredhutch.bsky.social SABCS24 wrap story w/insights into #cancer treatments & #cannabis; #ctDNA; #obesity & #epigenetics, #FES-PET & much more. #cansky #oncocsky #medsky #bcsm @thankscancer.bsky.social www.fredhutch.org/en/news/cent...fredhutch.orgWhat’s new in breast cancer research? SABCS24 looks at ctDNA, AI and ‘right-sizing’ treatmentMore than 11,000 researchers, clinicians, patient advocates and drugmakers gathered last week at the San Antonio Breast Cancer Symposium to share the latest treatments, tricks and tools to take down b... 0139
Paige @eppolmo.bsky.social · 14/12/2024Thank you to all of the advocates and researchers/scientists who shared throughout the week from SA. Information is power and you are giving patients power when you share. #bcsm #oncsky 010
Reposted by PaigeIlana Schlam @ilanaschlam.bsky.social · 13/12/2024Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 @oncoalert.bsky.social 04619
Reposted by PaigeSarah Sammons MD @drsarahsammons.bsky.social · 13/12/2024Dr Kaelin gave a very thought provoking talk. He argues single agent therapies will never cure cancer due to resistance. Our chance is cure will come with multiple non-cross resistant therapies, challenging current paradigms. #bcsm 2268
Reposted by PaigeSherry Shen, MD @sherryshenmd.bsky.social · 13/12/2024When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC! 2134
Reposted by PaigeKelly Shanahan @stage4kelly.bsky.social · 12/12/2024“ChatGPT can be used for more than college students cheating on essays” Dr Erika Hamilton explains how Sarah Cannon uses this to match patients to trials. #SABCS24 031
Reposted by PaigeSarah Sammons MD @drsarahsammons.bsky.social · 11/12/2024RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor. 2nd line PFS >11 months with fulvestrant. Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores. Hoping this one moves forward! #SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social 22211
Reposted by PaigeStephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 11/12/2024🧩How could these puzzle pieces fit? @DrHBurstein suggests one approach ⬇️ #SABCS24 @oncoalert.bsky.social 0127
Reposted by PaigeMargaret Gatti-Mays, MD MPH @drgattimays.bsky.social · 11/12/2024#EMBER3 results presented @sabcs.bsky.social #SABCS24 by @breastcancerdoc.bsky.social Main take aways: 1) Imlunestrant ⬆️ PFS > SOC in 1L, ESR1 mut, mER+ BC 2) Imlunestrant + abemaciclib ⬆️ PFS in 1L mER+ BC irrespective of ESR1 or PIK3CA mut 3) Imlunestrant ⬇️ CNS progression 4) OS immature #bcsm 144
Reposted by PaigeDana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · 11/12/2024Dr. Rinath Jeselsohn discusses #SERDS and the targeting of ER and #PI3K pathway in the #SABCS24 Poster Spotlight Session. 031
Paige @eppolmo.bsky.social · 11/12/2024Such important information. But what about in the MBC setting with ER+ disease. Especially with ILC that loves to wonder around the pelvic area. 141
Reposted by PaigeFumiko Ladd Chino, MD FASCO @fumikochino.bsky.social · 08/12/2024"For both patients and providers, prior authorization can feel like an unfair game they are designed to lose." Honored to work w/ Dr @nathangray.bsky.social on a graphic op-ed out now @usatoday.com on how #PriorAuth can leave some patients literally dying in pain. www.usatoday.com/story/opinio...usatoday.comFor patients and doctors, insurance prior authorization can be a dangerous game | OpinionDoctors trying to get patients necessary drugs and procedures stymied by health insurance prior authorization. It's not a game. It's life and death. 610545
Reposted by PaigeMatt Sikora @mjsikora.bsky.social · 06/12/2024Exciting update to our #lobular breast cancer work with DNA repair and PARP inhibition, ahead of @sabcs.bsky.social next week! #oncosky #bcsm www.biorxiv.org/content/10.1... Despite lacking "BRCA-like" mutations and features, we find ILC models are sensitive to PARPi in vivo. Why? 🧵 1/nbiorxiv.orgCo-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breastInvasive lobular carcinoma of the breast (ILC) are typically estrogen receptor α (ER)-positive and present with biomarkers of anti-estrogen sensitive disease, yet patients with ILC face uniquely poor ... 2278
Reposted by PaigeMatt Sikora @mjsikora.bsky.social · 25/11/2024Hey #oncosky and 🧪 friends - so glad you're here! A quick (re)intro to the Sikora Lab (www.sikoralab.com): We study: 1) #lobular breast cancer and its complicated relationship w estrogen. 2) gyn / ovarian cancer, metabolic parallels w #lobular, and genetic links to health disparities. 1/nsikoralab.comHomewelcome to the sikora lab 2264
Reposted by PaigeWendy Woodward, MD, PhD @ibcradiation.bsky.social · 23/11/2024More #thinkibc inflammatory breast cancer community on 🦋🦋 #bcsm Now the incomparable Dr. Lim!! #oncsky @talkibc.bsky.social @mdanderson.bsky.social @debeblab.bsky.social 🎉🎉 061
Reposted by PaigeFumiko Ladd Chino, MD FASCO @fumikochino.bsky.social · 20/11/2024Folded my 1st cranes for pts completing #radiation this week MD Anderson. I fold cranes as a small private gesture as a bell alternative; when I give them I explain they are a symbol of hope & healing. Paper -like hope- is both fragile & incredibly strong. It's a tiny thing but I do it with love. ❤️ 10796
Reposted by PaigeAmy Beumer @amybeumer.bsky.social · 20/11/2024As a patient clinical trials are so hard to identify. This new algorithm could help physicians but also patients! We need easy to use, reliable clinical trial matching. 131
Reposted by PaigeIlana Schlam @ilanaschlam.bsky.social · 17/11/2024Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes! 37216
Reposted by PaigePaolo Tarantino, MD @ptarantinomd.bsky.social · 17/11/2024Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio! 39534
Reposted by PaigeGeorge Sflomos @georgesflomos.bsky.social · 16/11/2024Congratulations to Steffi Oesterreich, the 2024 San Antonio Breast Cancer Symposium AACR Distinguished Lectureship in BC research. This well-earned recognition reflects your dedication and research for ER+ BC and lobular BC patients. I greatly appreciate your research, inspiration, and teamwork.aacr.orgAward Recipients Announced for the 2024 San Antonio Breast Cancer SymposiumThe San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor two researchers for their significant contributions to breast ca... 091
Reposted by PaigeDr. Don S Dizon @drdonsdizon.bsky.social · 16/11/2024Finishing up a trip to Portugal, where I talked on social media in Oncology. I got a question about whether there was an ethical argument for why clinicians should be on social media. My answer: I do think there is an ethical imperative. 1/5 1129
Reposted by PaigePaolo Tarantino, MD @ptarantinomd.bsky.social · 15/11/2024Hello friends! Smells like clean air in here. Let’s make it grow! 🦋 0186
Reposted by PaigeProject Life @projectlifembc.bsky.social · 14/11/2024We have launched our new initiative, Project OUTreach to resource and serve those in the LGBTQIA+ community living with MBC. Please share with your networks. www.projectlifembc.com/project-outr... #transcareMBC #LGBTQIA+ #MBCsupportprojectlifembc.comProject OUTreach | Project Life MBC 397
Reposted by PaigeFumiko Ladd Chino, MD FASCO @fumikochino.bsky.social · 12/11/2024"the new generation of cancer survivor [is] younger, less financially secure, and still having to navigate life after treatment, from dating to career, sex and child rearing" So glad that #AYAcsm #survonc #financialToxicity & #MBC issues are getting time on NPR www.npr.org/2024/11/11/n... 15421
Reposted by PaigebioRxiv Cancer Bio @biorxiv-cancer.bsky.social · 12/09/2023Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures and actionable driver mutations www.biorxiv.org/content/10.1101/202… biorxiv.orgSpatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures and actionable driver mutations https://www.biorxiv.org/content/10.1101/2023.09.09.557013v1 Mixed invasive ductal and lobular carcinoma (mDLC) is a rare histologic subtype of breast cancer dis 032
Reposted by Paige@doublewhammied @doublewhammied.bsky.social · 14/11/2024Sharing my latest story 4 @fredhutch.bsky.social on their #Metastatic #BreastCancer #Survivorship event Nov 2. Lots of practical advice 4 those w/#MBC, incl financ'l resources, tips on sexual health, exercise. #QOL @thankscancer.bsky.social @coffeemommy.bsky.social www.fredhutch.org/en/news/cent...fredhutch.orgSurviving and thriving with metastatic breast cancerFred Hutch Cancer Center brought together a host of experts on November 2 to share tips, tools, resources and strategies for creating the best quality of life while living with metastatic breast cance... 1215
